Pediatric AML

Evaluation of the Clinical Outcomes Among the Pediatric Low-risk Acute Myeloid Leukemia Patients Who Received Four Versus Five Cycles of Chemotherapy: Single-center Study
Response of Relapsed/ Refractory Pediatric AML to Clad-AraC